N4P Stock Overview
A specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
N4 Pharma Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0057 |
| 52 Week High | UK£0.0095 |
| 52 Week Low | UK£0.0037 |
| Beta | -0.25 |
| 1 Month Change | -8.00% |
| 3 Month Change | -8.00% |
| 1 Year Change | -23.33% |
| 3 Year Change | -82.31% |
| 5 Year Change | -82.31% |
| Change since IPO | -90.98% |
Recent News & Updates
Recent updates
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth
Oct 11
Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Jul 06Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth
Dec 07
Shareholder Returns
| N4P | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -17.9% | 2.1% | 0.3% |
| 1Y | -23.3% | 10.1% | 12.1% |
Return vs Industry: N4P underperformed the UK Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: N4P underperformed the UK Market which returned 12.1% over the past year.
Price Volatility
| N4P volatility | |
|---|---|
| N4P Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: N4P's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: N4P's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 5 | Nigel Theobald | www.n4pharma.com |
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
N4 Pharma Plc Fundamentals Summary
| N4P fundamental statistics | |
|---|---|
| Market cap | UK£2.27m |
| Earnings (TTM) | -UK£1.08m |
| Revenue (TTM) | UK£5.86k |
387.4x
P/S Ratio-2.1x
P/E RatioIs N4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N4P income statement (TTM) | |
|---|---|
| Revenue | UK£5.86k |
| Cost of Revenue | UK£89.18k |
| Gross Profit | -UK£83.32k |
| Other Expenses | UK£994.73k |
| Earnings | -UK£1.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0027 |
| Gross Margin | -1,422.02% |
| Net Profit Margin | -18,399.86% |
| Debt/Equity Ratio | 0% |
How did N4P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 06:18 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
N4 Pharma Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emma Ulker | Allenby Capital Limited |